Alterity raises $35M in placement to international and Australian institutions and sophisticated investors. October 16, 2020August 16, 2022
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease December 4, 2023December 4, 2023
Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference March 10, 2021August 16, 2022